Latest Biotech News

Tubulis closed one of Europe’s largest Series C rounds—raising €308 million (reported variously as ~$356–361 million)—to advance its clinical‑stage antibody‑drug conjugate (ADC) portfolio and...

Lonza announced Swissmedic has granted GMP approval for its new aseptic drug‑product filling line in Stein, Switzerland, enabling contained manufacturing of highly potent biologics including ADCs....

Researchers published DeepSomatic, a deep‑learning platform that improves somatic small‑variant detection across short‑ and long‑read sequencing technologies, and released a set of public...

Google’s C2S‑Scale 27B foundation model, developed with Yale and based on Gemma, generated a novel hypothesis identifying an interferon‑conditional amplifier that could boost antigen presentation...

Tempus entered a multi‑year collaboration with Whitehawk Therapeutics to apply Tempus’ de‑identified multimodal real‑world database to guide biomarker discovery and indication prioritization...

Pelage Pharmaceuticals closed a $120 million Series B to finance a Phase III program for PP‑405, a topical small molecule designed to activate dormant hair‑follicle stem cells. Investors included...

Adcytherix announced a €104 million Series A to propel its lead antibody‑drug conjugate program toward first‑in‑human studies. The French biotech raised the financing from institutional...

Merck KGaA’s MilliporeSigma announced a definitive agreement to acquire the chromatography business of JSR Life Sciences, broadening its downstream processing portfolio with JSR’s Protein A resins...

Novo Nordisk agreed to acquire global rights to zaltenibart from Omeros in a deal that pays Omeros $340 million upfront and could reach $2.1 billion with milestones. The antibody inhibits MASP‑3,...

Tubulis closed a €308 million (about $356 million) Series C to accelerate clinical development of its antibody‑drug conjugate portfolio, led by lead candidate TUB‑040. The round is among the...

Pelage Pharmaceuticals raised $120 million in an oversubscribed Series B to support a phase III program for PP‑405, a topical small molecule designed to activate dormant hair‑follicle stem cells....

Kailera Therapeutics secured $600 million in a Series B led by Bain Capital Private Equity to advance KAI‑9531, a weekly injectable targeting the same receptors as existing dual‑agonist obesity...

The U.S. Department of Health and Human Services awarded Tempus AI a roughly $60 million ARPA‑H contract to provide testing and research services aimed at developing biomarker‑driven adaptive...

In a GeneDx pilot presented at ASHG, Illumina’s constellation mapped‑read technology outperformed other methods at detecting challenging, hard‑to‑map variants implicated in rare disease. The pilot...

Pacific Biosciences announced Sprq‑Nx chemistry and a program to reuse SMRT cell consumables for high‑volume customers, aiming to lower long‑read whole‑genome costs to roughly $250–$300 per genome...

Researchers at Rensselaer Polytechnic Institute developed a regenerated cellulose membrane with peptide ligands that outperformed commercial chromatography columns for purifying mRNA therapeutics....

Myeloid Therapeutics announced a rebrand to Create Medicines and broadened its platform beyond myeloid programming to include in‑vivo mRNA‑based programming of T cells and NK cells using lipid...

A team published DeepSomatic in Nature Biotechnology as a somatic small‑variant caller that works across short‑ and long‑read sequencing technologies and released seven public somatic variant...

Novo Nordisk agreed to license global rights to Omeros’ MASP‑3 antibody zaltenibart, committing up to $2.1 billion in milestones and royalties. The deal gives Novo immediate control of a mid‑stage...

Tubulis closed a major Series C financing (reported in euros) to accelerate clinical development of its next‑generation antibody‑drug conjugates (ADCs). The round—among the largest European...